The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis - Takeaways - MDSpire

The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis

  • By

  • Jiang Yu

  • Yong Peng

  • May 20, 2026

  • 0 min

Share

  • 1

    Metabolic dysfunction-Associated Steatohepatitis (MASH) is a progressive liver disease linked to obesity and metabolic syndrome.

  • 2

    MASH is characterized by hepatic steatosis, inflammation, hepatocellular injury, and can progress to cirrhosis and hepatocellular carcinoma.

  • 3

    Insulin resistance plays a crucial role in MASH pathogenesis by promoting lipid accumulation and increasing hepatocyte vulnerability.

  • 4

    Current therapeutic strategies for MASH are limited, necessitating the exploration of immunometabolic pathways for effective treatments.

  • 5

    Precision medicine approaches targeting multiple pathways may offer promising directions for individualized MASH treatment.

Original Source(s)

The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis

  • by Jiang Yu, Yong Peng

  • May 20, 2026

Related Content

Impaired Iron-Copper Metabolic Axis in Human Intestinal Mucosa After Roux-en-Y Gastric Bypass: A Prospective Transcriptomic Study Using Double-Balloon Enteroscopy

Mechanisms and Therapeutic Promise of Electroacupuncture for Non-Alcoholic Fatty Liver Disease

Addressing Tamoxifen-Associated Weight Gain: Lifestyle and Pharmacotherapy Options

Tamoxifen is commonly prescribed in hormone receptor-positive breast cancer but also associated with weight gain, which can complicate survivorship care. This narrative review summarizes evidence on tamoxifen-associated weight gain and outlines pharmacologic weight management options in this population.